Teva Pharma (TEVA) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Teva Pharma (TEVA) Intends to Issue $4B Offering of Sustainability-linked Senior Notes
October 27, 2021 7:16 AM EDTTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today its intention to issue $4,000,000,000 of sustainability-linked senior notes. The notes offering reflects Tevas strong environmental, social and governance (ESG) commitment to some of the greatest challenges of our time by setting novel ambitious targets to increase access to medicines in low and middle-income countries by 150%, and new ambitious climate action targets, including a 25% reduction of Scope 1 and 2 greenhouse emissions by 2025 in alignment with the Paris Climate Agreement.
This sustainability-linked financing framework was validated by two Second Party Opinions (SPO), which were provided by... More
Teva Pharma (TEVA) and MODAG Collaborate on Neurodegenerative Disease Drug Candidate
October 26, 2021 4:45 PM EDTTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433.
Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease... More
